Anna Broder, MD, MSc
Albert Einstein College of Medicine
Dr. Broder is studying the effectiveness of hydroxychloroquine in reducing the mortality rate of patients with systemic lupus erythematosus (SLE) who develop end-stage renal disease. Hydroxychloroquine is an antimalarial drug prescribed to less than 30% of these patients. Although the development of end stage renal disease is one of the most common complications of SLE, there are no studies to date on how to improve outcomes or if hydroxychloroquine is effective. Dr. Broder's study will shed light on the treatment, so that rheumatologists can make more informed decisions when treating SLE patients like Ruth.